Latest news about Boston Commerce
Boston Commerce
5.81
+0.11(+1.93%)
Company Performance:
View Company Insights1D+1.93%
1M-23.55%
6M-11.97%
1Y-28.45%
5Y-72.20%
More news about Boston Commerce
13Feb 26
Boston Commerce Limited Reports Q3FY26 Results with Revenue Decline and Net Loss
Boston Commerce Limited reported Q3FY26 results showing revenue of ₹5.85 lakhs, down from ₹24.47 lakhs in Q2FY26, resulting in a net loss of ₹1.44 lakhs. However, the nine-month period demonstrated strong recovery with total revenue of ₹48.37 lakhs and net profit of ₹6.51 lakhs, compared to zero revenue and ₹5.68 lakhs loss in the corresponding period last year. The company maintained its paid-up equity share capital at ₹700.22 lakhs with earnings per share of ₹0.09 for the nine-month period.
27Nov 25
Boston Bio Systems Limited Rebrands as Boston Commerce Limited
Boston Bio Systems Ltd. (BSE: 531458) has officially changed its name to Boston Commerce Limited, as approved by the Ministry of Corporate Affairs on November 27, 2025. The name change was authorized by shareholders through a Special Resolution at the Annual General Meeting on September 30, 2025. Recent financial data shows significant changes, with total assets increasing by 40.57% year-on-year to ₹14.90 crore, driven by an 89.58% rise in current assets. Non-current liabilities saw a dramatic 4500% increase, while total equity decreased by 9.23%.
14Nov 25
Boston Bio Systems Reports Q2 Profit, Appoints New Auditors
Boston Bio Systems Ltd. (BSE: BOSTONBIO) announced financial results for Q2 and H1 FY2025-26, showing significant improvement. Q2 revenue was ₹24.47 crore with a profit after tax of ₹3.94 crore, compared to a loss in the previous year. H1 revenue reached ₹42.52 crore with ₹7.95 crore profit. The company also appointed Mr. Shashank Kumar as Secretarial Auditor and Mr. Nishant Sharma as Internal Auditor for FY2025-26.
13Oct 25
Boston Bio Systems Limited Announces Key Leadership Changes in Company Secretarial Position
Boston Bio Systems Ltd. has appointed Ms. Nisha Yadav as the new Company Secretary and Compliance Officer, effective October 13, 2025. She replaces Ms. Mandeep Kaur, who has resigned from the position. Ms. Yadav is a qualified Company Secretary with over 4 years of experience in corporate law matters. The changes were approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee.
04Sept 25
Boston Bio Systems Announces Major Corporate Changes, Including New Auditor Appointment
Boston Bio Systems Ltd. (BSE: 531458) has announced significant corporate changes following a board meeting. The company appointed M/s Sunit M Chhatbar & Co. as the new Statutory Auditor, replacing M/s Nahar V & Company. The Board approved changes to the Memorandum of Association, expanding potential business activities to include IT services, agriculture, real estate, and e-commerce. A new set of Articles of Association was also approved. These changes are subject to shareholder approval at the upcoming 30th Annual General Meeting.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare Technologies
Nephrocare Health Services
Krsnaa Diagnostics
Suraksha Diagnostic
One Global Service Provider
Health X Platform
3B BlackBio DX
1,647.00
(-2.50%)
1,311.30
(-4.13%)
523.80
(-3.60%)
524.40
(+1.39%)
658.20
(+0.04%)
537.05
(-0.22%)
273.30
(+0.61%)
715.00
(-3.79%)
318.25
(-3.05%)
1,173.80
(+1.22%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
